The Food and Drug Administration announced on January 26, 2023, that the monoclonal antibody (mAbs) Evusheld™ is not currently authorized for preexposure prophylaxis against SARS-CoV-2 virus infection in the United States. The FDA based this action... READ →
Precision Vaccinations/ January 28th, 2023
Eliminating fake vaccine news with pharmacist, nurse, and physician review.
Jan 27 • 3:58 pm CST
Jan 27 • 4:39 am CST
In the first episode of "Intention to Treat," the New England Journal of Medicine editor-in-chief Eric Rubin and his colleague at the U.S. FDA Vaccine Advisory Committee, Dr. Paul Offit, director of the Vaccine Education Center... READ →
Jan 26 • 2:06 pm CST
The World Health Organization (WHO) Influenza Update N° 437 report recently confirmed influenza activity decreased globally but remained somewhat elevated due to activity in the northern hemisphere. In the countries of North America, most indicators of... READ →
Jan 26 • 9:12 am CST
AC Immune SA today announced the first interim safety, tolerability, and immunogenicity findings from the Phase 1b/2 ABATE trial of its anti-amyloid-beta (Abeta) vaccine ACI-24.060 in patients with prodromal Alzheimer's disease (AD). Early results from the... READ →
Jan 26 • 7:48 am CST
TG Therapeutics, Inc. today announced the commercial launch of BRIUMVI™, for treating relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI is the first and... READ →
For more articles, try our search.